Gilead Data Suggest Role For ACC Inhibition In NASH

Gilead Sciences Inc. presented data at the American Association for the Study of Liver Diseases annual meeting indicating a potential role for acetyl-coA-carboxylase (ACC) inhibition in the treatment of non-alcoholic steatohepatitis (NASH), as the higher of two doses tested in a Phase II study showed a statistically significant reduction in the buildup of fat in the liver compared to placebo after 12 weeks of treatment.

Presented as a late-breaking abstract on Oct, 24, the last day of the conference in Washington, DC, GS-0976 reduced hepatic steatosis by a mean 28.9% from baseline in a 49-patient...